Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Preliminary Efficacy of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

NCT06049667 is registered in ClinicalTrials.gov with Nanjing Chia-tai Tianqing Pharmaceutical as lead sponsor.

NCT NCT06049667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06049667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Preliminary Efficacy of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
Lead sponsor
Nanjing Chia-tai Tianqing Pharmaceutical
Phase
Phase 1
Overall status
Recruiting
Start date
August 7, 2023
Completion date
August 31, 2026
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory acute myeloid leukemia (aml)